Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RMC-4630 + Sotorasib in KRASG12C mutant NSCLC
NCT05054725Phase 2Completed
- Sponsor
- Revolution Medicines
- Start
- Dec 2021
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of vociprotafib in non-small cell lung cancer (NSCLC), sponsored by Revolution Medicines. Started Dec 2021; status: completed.
02
Drugs
vociprotafib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05054725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05054725.